S Kim1, J-H Choi2, M Kang3, J-K Cha4, J-T Huh2. 1. From the Departments of Radiology (S.K., M.K.). 2. Neurosurgery (J.-H.C., J.-T.H.). 3. From the Departments of Radiology (S.K., M.K.) myongjin.kang@gmail.com. 4. Neurology (J.-K.C.), Busan-Ulsan Regional Cardio-Cerebrovascular Disease Center, Dong-A University Hospital, Busan, Republic of Korea.
Abstract
BACKGROUND AND PURPOSE: Stent-assisted coiling of intracranial aneurysms requires antiplatelet therapy, typically aspirin and clopidogrel to prevent thromboembolic complications. There is a substantial concern that tirofiban may increase the risk of hemorrhage when used as an antiplatelet premedication in ruptured intracranial aneurysms. Our aim was to evaluate the safety and efficacy of intravenous tirofiban administration, instead of oral dual antiplatelet agents, as an antiplatelet premedication for stent-assisted coiling in patients with acutely ruptured intracranial aneurysms. MATERIALS AND METHODS: We conducted a retrospective review of a data base containing a consecutive series of patients who underwent stent-assisted coiling for acutely ruptured intracranial aneurysms between March 2010 and January 2015. Intravenous tirofiban was administered to all patients before stent-assisted coiling, instead of premedication with loading doses of aspirin or clopidogrel. RESULTS: Forty patients with 41 aneurysms received intravenous tirofiban and underwent stent-assisted coiling. None of the patients had a newly developed intracerebral hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage. Intraprocedural aneurysmal rupture occurred in 2 patients (5%). Cerebral infarction developed in 2 patients (5%). Ventriculostomy-related hemorrhage was seen in 2 of 10 patients in whom ventriculostomy was performed before or after coiling. Thirty-four (85%) patients had a good outcome (Glasgow Outcome Score of 4 or 5) at the time of discharge, but 1 patient died of cardiac arrest. None of the patients developed thrombocytopenia, retroperitoneal, gastrointestinal, or genitourinary bleeding related to tirofiban administration. CONCLUSIONS: In our study, tirofiban showed a low risk of symptomatic hemorrhagic or thromboembolic complications. Tirofiban may offer a safe and effective alternative as an antiplatelet premedication during stent-assisted coiling of acutely ruptured intracranial aneurysms.
BACKGROUND AND PURPOSE: Stent-assisted coiling of intracranial aneurysms requires antiplatelet therapy, typically aspirin and clopidogrel to prevent thromboembolic complications. There is a substantial concern that tirofiban may increase the risk of hemorrhage when used as an antiplatelet premedication in ruptured intracranial aneurysms. Our aim was to evaluate the safety and efficacy of intravenous tirofiban administration, instead of oral dual antiplatelet agents, as an antiplatelet premedication for stent-assisted coiling in patients with acutely ruptured intracranial aneurysms. MATERIALS AND METHODS: We conducted a retrospective review of a data base containing a consecutive series of patients who underwent stent-assisted coiling for acutely ruptured intracranial aneurysms between March 2010 and January 2015. Intravenous tirofiban was administered to all patients before stent-assisted coiling, instead of premedication with loading doses of aspirin or clopidogrel. RESULTS: Forty patients with 41 aneurysms received intravenous tirofiban and underwent stent-assisted coiling. None of the patients had a newly developed intracerebral hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage. Intraprocedural aneurysmal rupture occurred in 2 patients (5%). Cerebral infarction developed in 2 patients (5%). Ventriculostomy-related hemorrhage was seen in 2 of 10 patients in whom ventriculostomy was performed before or after coiling. Thirty-four (85%) patients had a good outcome (Glasgow Outcome Score of 4 or 5) at the time of discharge, but 1 patient died of cardiac arrest. None of the patients developed thrombocytopenia, retroperitoneal, gastrointestinal, or genitourinary bleeding related to tirofiban administration. CONCLUSIONS: In our study, tirofiban showed a low risk of symptomatic hemorrhagic or thromboembolic complications. Tirofiban may offer a safe and effective alternative as an antiplatelet premedication during stent-assisted coiling of acutely ruptured intracranial aneurysms.
Authors: Baojin Zhu; Mark B Effron; M Pandurang Kulkarni; Ying G Li; Joseph A Jakubowski; Debra L Miller; Brian A Baker; Junxiang Luo; David S Small; Kenneth J Winters Journal: J Cardiovasc Pharmacol Date: 2011-03 Impact factor: 3.105
Authors: Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Udaya S Tantry; Tania Gesheff; Cheryl Wei; Renli Teng; Mark J Antonino; Shankar B Patil; Arun Karunakaran; Dean J Kereiakes; Cordel Parris; Drew Purdy; Vance Wilson; Gary S Ledley; Robert F Storey Journal: Circulation Date: 2009-11-18 Impact factor: 29.690
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: Kaustubh Limaye; Mario Zanaty; Joseph Hudson; Daichi Nakagawa; Sami Al Kasab; Carlos Alvarez; Sudeepta Dandapat; David K Kung; Santiago Ortega-Gutierrez; Pascal Jabbour; Edgar A Samaniego; David Hasan Journal: Neurosurgery Date: 2019-12-01 Impact factor: 4.654
Authors: Sarah L Clark; Kimberly Levasseur-Franklin; Mehrnaz Pajoumand; Megan Barra; Michael Armahizer; Deepa V Patel; Katleen Wyatt Chester; Andrea P Tully Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210
Authors: Edgar A Samaniego; Emilee Gibson; Daichi Nakagawa; Santiago Ortega-Gutierrez; Mario Zanaty; Jorge A Roa; Pascal Jabbour; David M Hasan Journal: Stroke Vasc Neurol Date: 2019-02-03